In the context of CAR-T therapy of hematologic malignancies, such as those targeting CD19, due to the expression of CD19 by both normal cells and malignant blasts, CAR-T therapy results in the elimination of both of these cells leading to a phenomenon known as “B-cell aplasia” (235). Here, CD19 is linked to hematologic disorder.